The silence around perimenopause is sustained by what research misses, what training skips, what funding overlooks, and what care fails to connect.
If you are a woman somewhere in your forties, some of this may already be happening to you, and no one may have told you why.
It begins quietly. You wake up one morning and your knees ache, and you cannot think of a single reason why. A few weeks later your shoulder stiffens and you cannot reach the top shelf. You are fine, then you are crying, then you are fine again. You are hot. You are cold. Some nights you wake at three in the morning soaked through, heart racing, and you lie there wondering what is wrong with you. You are tired in a way that sleep does not fix.
You do not connect any of it. Why would you? No one told you these things travel together.
This is perimenopause, the years before the last period, and for many women it stretches close to a decade. Some women are hit hard. Some barely notice the shift. Many feel a version of it and reach for an explanation that has nothing to do with hormones, because that is the only story they were ever handed.
The knee pain may have a name. So may the frozen shoulder. In late 2024 a group of researchers proposed a term for this wider cluster, the musculoskeletal syndrome of menopause. The numbers are not small. Around seven in ten women in the transition report joint and muscle pain, and for roughly a quarter of them it is bad enough to change how they move through an ordinary day. The pain travels, turning up in one joint and then another.
This is one cluster among many. The same hormonal shift can arrive as anxiety, broken sleep, brain fog, a temper that surprises you, heavier bleeding, a body that stops responding the way it used to. Different women meet it through different doors.
What they share is the dismissal. The tests come back clean. The bloodwork looks normal. She is told she is just getting older, or that she should lose some weight, or that it is stress. She goes home with a body that feels ten years past where it was six months ago, and no words to explain it. A normal test result should not end the conversation while the pattern is still speaking.
Here is the part that should unsettle us. That cluster had no name until recently, in a field that has studied women’s bodies for more than a century. Women felt it the whole time. The knowledge had simply not been built, named, or taught with enough seriousness.
Money does more than pay for care. It decides which questions get asked, which symptoms get named, and which women are studied closely enough to be believed.
This is why the news in June mattered. Melinda French Gates put another 215 million dollars into women’s health, and she named midlife and menopause as a clear priority. Her total commitment over two years now sits above 600 million. She has been open about what she is doing. She is sending a signal to other people with money that this is a category worth backing, and that women’s health does not have to remain the thing everyone calls important and too few people fund.
I want to be glad about this, and I am. More money and more attention can move research that should have moved decades ago. The silence has lasted long enough, and the cost of it is finally too visible to ignore.
Then comes the harder question. Where is the signal pointed?
Most of what medicine knows about this transition was learned from women in high-income countries, and mostly from white women. The largest and longest-running study of the menopause transition we have, the Study of Women’s Health Across the Nation, followed women across the United States. It did something rare and worth crediting. It included Black, Hispanic, Chinese, Japanese and white women, and it showed that the experience is not the same across them.
Black women tend to reach menopause earlier, stay in the transition longer, carry heavier and longer-lasting symptoms, and are less likely to be offered treatment for any of it. Researchers have a word for the wear that chronic stress and discrimination put on the body over time. They call it weathering.
Now hold that study next to the woman in Nairobi, Cotonou, Maseru, Bissau or Ndjamena. The evidence that shaped her doctor’s training was not built on her body. The studies that exist on African women are comparatively few, scattered and small. Those few studies suggest that some women may reach menopause earlier than the textbook age of fifty-one, often somewhere in their late forties, with their own pattern of symptoms. We are mostly guessing.
Her clinician, if she has one, likely trained on material that rarely covered menopause in any depth. She arrives with knees that ache and nights that burn, and the system meets her with a shrug shaped by data that rarely included women like her.
I keep returning to the same thought across this series. The failure here belongs to no single person. Researchers studied the bodies that were easiest to reach. Medical training left a gap and never closed it. Health systems built around acute illness kept little room for a slow transition. Funding followed attention, and attention was elsewhere. Women, taught that this was private and a little shameful, kept the silence with one another. All of us could have done better. All of us still can.
Talk about it. Name the knee pain to your sister, your friend, your doctor. Ask whether what you are feeling could be part of the transition, and keep asking if the first answer is that you are simply getting older.
Clinicians can read the pattern even when the test result reads normal. Funders can send the new money toward the women who have been counted least. Researchers can build evidence that finally includes the woman in Nairobi, Cotonou, Maseru, Bissau and Ndjamena.
The woman in Maseru deserves to be counted inside the evidence. Right now she is spoken for by data built on other women.
This phase was always going to come. The silence around it did not have to.